TREA

79340796 - BRRT

Follow

Information

  • Trademark
  • 79340796
  • Serial Number
    79340796
  • Registration Number
    7159645
  • Filing Date
    February 25, 2022
    2 years ago
  • Registration Date
    September 12, 2023
    a year ago
  • Transaction Date
    January 08, 2024
    11 months ago
  • Status Date
    September 12, 2023
    a year ago
  • Published for Opposition Date
    June 27, 2023
    a year ago
  • Location Date
    September 12, 2023
    a year ago
  • Status Code
    700
  • Current Location
    PUBLICATION AND ISSUE SECTION
    Employee Name
    LEASER, ANDREW C
  • Attorney Docket Number
    571396
    Attorney Name
    Andrew D. Price & Paula E. Hopkins
    Law Office Assigned Location Code
    M80
  • Owners
Information
Mark Drawing Code
4000
Mark Identification
BRRT
Case File Statements
  • GS0051: Pharmaceuticals, for use in the treatment and prevention of disease in the field of oncology for both solid and liquid tumours, for use in the treatment and prevention of metabolic disease, urology and renal disease, in the cardiovascular field, in the field of hematology, for use in the treatment and prevention of respiratory, chronic and acute inflammatory disease and auto-immune disorders, gastrointestinal disease, bacterial and viral infectious disease, neurological and psychiatric disorders; pharmaceutical products and preparations for use in the treatment and prevention of disease in the field of oncology; pharmaceutical products and preparations for use in the treatment and prevention of disease in the field of ophthalmology; pharmaceutical products and preparations for use in the treatment and prevention of disease in the field of neurology; anti-infective pharmaceutical products and preparations; pharmaceutical products and preparations for the treatment and/or prevention of respiratory disease; pharmaceutical products and preparations for the treatment and/or prevention of cardiovascular disease; pharmaceutical products and preparations for the treatment and/or prevention of metabolic disease; pharmaceutical products and preparations for the treatment and/or prevention of viral infections; pharmaceutical products and preparations for use in diagnostics and imaging, namely, clinical imaging agents; pharmaceutical products and preparations for the treatment and/or prevention of renal disease; pharmaceutical products and preparations for the treatment and/or prevention of gastrointestinal disease; pharmaceutical products and preparations for the treatment and/or prevention of muscular skeletal disease
  • GS0441: Medical services; medical testing for diagnostic or treatment purposes; healthcare services for the treatment and prevention of disease in the field of oncology for both solid and liquid tumours, for the treatment and prevention of metabolic disease, urology and renal disease, cardiovascular diseases, for the treatment and prevention of disease in the field of hematology, for the treatment and prevention of respiratory, chronic and acute inflammatory disease and auto-immune disorders, gastrointestinal disease, bacterial and viral infectious disease, neurological and psychiatric disorders; pharmaceutical compounding services; medical consulting services; advisory services relating to pharmaceuticals; consultancy and information services relating to pharmaceuticals, namely, medical and pharmaceutical consultation and providing information relating to diagnostic, prophylactic and therapeutic properties of pharmaceuticals; medical services in the field of oncology; medical services in the field of ophthalmology; medical services in the field of neurology; medical services in the field of anti-infectives; medical services in the field of respiratory disease; medical services in the field of cardiovascular disease; medical services in the field of metabolic disease; medical services in the field of the treatment and/or prevention of viral infections; medical services in the field of diagnostics and imaging; medical services in the field of renal disease; medical services in the field of gastrointestinal disease; medical services in the field of muscular skeletal disease; pharmaceutical compounding services in the field of oncology; pharmaceutical compounding services in the field of ophthalmology; pharmaceutical compounding services in the field of neurology; pharmaceutical compounding services in the field of anti-infectives; pharmaceutical compounding services in the field of respiratory disease; pharmaceutical compounding services in the field of cardiovascular disease; pharmaceutical compounding services in connection with metabolic disease; pharmaceutical compounding services in connection with the treatment and/or prevention of viral infections; pharmaceutical compounding services in connection with diagnostics and imaging; pharmaceutical compounding services in connection with renal disease; pharmaceutical compounding services in connection with gastrointestinal disease; pharmaceutical compounding services in connection with muscular skeletal disease; information, consultancy and advisory services relating to the aforesaid
  • GS0421: Scientific and technological services and research and design relating thereto, namely, scientific research, new product design services, and new study design services in the fields of the development of future human and veterinary medical treatments in the field of oncology for both solid and liquid tumors, metabolic disease, urology and renal disease, cardiovascular, hematology, respiratory, chronic and acute inflammatory disease and auto-immune disorders, gastrointestinal disease, bacterial and viral infectious disease, neurological and psychiatric disorders, diagnostic preparations and clinical imaging agents; industrial analysis and research services in the fields of oncology for both solid and liquid tumors, metabolic disease, urology and renal disease, cardiovascular, hematology, respiratory, chronic and acute inflammatory disease and auto-immune disorders, gastrointestinal disease, bacterial and viral infectious disease, neurological and psychiatric disorders, diagnostic preparations and clinical imaging agents; pharmaceutical research and development services; medical research and development services; pharmaceutical testing and medical and scientific research, namely, conducting clinical trials for others; medical and scientific research, namely, conducting clinical trials for others; research and development in the field of oncology; research and development in the field of ophthalmology; research and development in the field of neurology; research and development in the field of anti-infective pharmaceuticals; research and development in the field of respiratory disease; research and development in the field of cardiovascular disease; research and development in the field of metabolic disease; research and development in the field of antiviral drugs; research and development in the field of diagnostics and imaging; research and development in the field of renal disease; research and development in the field of gastrointestinal disease; research and development in the field of muscular skeletal disease; information consultancy and advisory services relating to the aforesaid
Case File Event Statements
  • 1/8/2024 - 11 months ago
    27 - FINAL DECISION TRANSACTION PROCESSED BY IB Type: FINO
  • 12/14/2023 - a year ago
    26 - FINAL DISPOSITION NOTICE SENT TO IB Type: FICS
  • 12/14/2023 - a year ago
    25 - FINAL DISPOSITION PROCESSED Type: FIMP
  • 12/12/2023 - a year ago
    24 - FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB Type: FICR
  • 12/1/2023 - a year ago
    23 - NEW REPRESENTATIVE AT IB RECEIVED Type: NREP
  • 9/12/2023 - a year ago
    22 - NOTICE OF REGISTRATION CONFIRMATION EMAILED Type: NRCC
  • 9/12/2023 - a year ago
    21 - REGISTERED-PRINCIPAL REGISTER Type: R.PR
  • 6/27/2023 - a year ago
    20 - OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED Type: NPUB
  • 6/27/2023 - a year ago
    19 - PUBLISHED FOR OPPOSITION Type: PUBO
  • 6/25/2023 - a year ago
    18 - NOTIFICATION PROCESSED BY IB Type: GPNX
  • 6/7/2023 - a year ago
    17 - NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB Type: OPNS
  • 6/7/2023 - a year ago
    16 - NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB Type: OP2R
  • 6/7/2023 - a year ago
    15 - NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED Type: NONP
  • 5/22/2023 - a year ago
    14 - APPROVED FOR PUB - PRINCIPAL REGISTER Type: CNSA
  • 4/21/2023 - a year ago
    13 - TEAS/EMAIL CORRESPONDENCE ENTERED Type: TEME
  • 4/20/2023 - a year ago
    12 - CORRESPONDENCE RECEIVED IN LAW OFFICE Type: CRFA
  • 4/20/2023 - a year ago
    11 - TEAS RESPONSE TO OFFICE ACTION RECEIVED Type: TROA
  • 11/21/2022 - 2 years ago
    10 - REFUSAL PROCESSED BY IB Type: RFNT
  • 10/28/2022 - 2 years ago
    9 - NON-FINAL ACTION MAILED - REFUSAL SENT TO IB Type: RFCS
  • 10/28/2022 - 2 years ago
    8 - REFUSAL PROCESSED BY MPU Type: RFRR
  • 9/24/2022 - 2 years ago
    7 - CHANGE OF NAME/ADDRESS REC'D FROM IB Type: ADCH
  • 9/11/2022 - 2 years ago
    6 - NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW Type: RFCR
  • 9/10/2022 - 2 years ago
    5 - NON-FINAL ACTION WRITTEN Type: CNRT
  • 9/9/2022 - 2 years ago
    4 - ASSIGNED TO EXAMINER Type: DOCK
  • 5/24/2022 - 2 years ago
    3 - APPLICATION FILING RECEIPT MAILED Type: MAFR
  • 5/20/2022 - 2 years ago
    2 - NEW APPLICATION OFFICE SUPPLIED DATA ENTERED Type: NWOS
  • 5/19/2022 - 2 years ago
    1 - SN ASSIGNED FOR SECT 66A APPL FROM IB Type: REPR